These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22521766)

  • 1. Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole.
    Dubreuil LJ; Mahieux S; Neut C; Miossec C; Pace J
    Int J Antimicrob Agents; 2012 Jun; 39(6):500-4. PubMed ID: 22521766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
    Chahine EB; Sourial M; Ortiz R
    Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
    Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
    Levasseur P; Girard AM; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1931-4. PubMed ID: 25583732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination.
    Jones RN; Holliday NM; Krause KM
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5036-9. PubMed ID: 26014937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of solithromycin against anaerobic bacteria from the normal intestinal microbiota.
    Weintraub A; Rashid MU; Nord CE
    Anaerobe; 2016 Dec; 42():119-122. PubMed ID: 27725229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor.
    Reck F; Bermingham A; Blais J; Casarez A; Colvin R; Dean CR; Furegati M; Gamboa L; Growcott E; Li C; Lopez S; Metzger L; Nocito S; Ossola F; Phizackerley K; Rasper D; Shaul J; Shen X; Simmons RL; Tang D; Tashiro K; Yue Q
    ACS Infect Dis; 2019 Jul; 5(7):1045-1051. PubMed ID: 30861342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative
    Goldstein EJC; Citron DM; Tyrrell KL; Leoncio E; Merriam CV
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The aerobic activity of metronidazole against anaerobic bacteria.
    Dione N; Khelaifia S; Lagier JC; Raoult D
    Int J Antimicrob Agents; 2015 May; 45(5):537-40. PubMed ID: 25813393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility pattern of oral gram negative anaerobes from Indian subjects.
    Bhat KG; Ingalagi P; Patil S; Patil S; Pattar G
    Anaerobe; 2021 Aug; 70():102367. PubMed ID: 33872790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility against metronidazole and carbapenem in clinical anaerobic isolates from Pakistan.
    Shafquat Y; Jabeen K; Farooqi J; Mehmood K; Irfan S; Hasan R; Zafar A
    Antimicrob Resist Infect Control; 2019; 8():99. PubMed ID: 31210928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.
    Falcone M; Viale P; Tiseo G; Pai M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):331-340. PubMed ID: 29373935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strain-specific anti-biofilm and antibiotic-potentiating activity of 3',4'-difluoroquercetin.
    Kho W; Kim MK; Jung M; Chong YP; Kim YS; Park KH; Chong Y
    Sci Rep; 2020 Aug; 10(1):14162. PubMed ID: 32843653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A β-lactamase inhibitor revival provides new hope for old antibiotics.
    Garber K
    Nat Rev Drug Discov; 2015 Jul; 14(7):445-7. PubMed ID: 26129790
    [No Abstract]   [Full Text] [Related]  

  • 20. Measurement of Free Plasma Concentrations of Beta-Lactam Antibiotics: An Applicability Study in Intensive Care Unit Patients.
    Schießer S; Hitzenbichler F; Kees MG; Kratzer A; Lubnow M; Salzberger B; Kees F; Dorn C
    Ther Drug Monit; 2021 Apr; 43(2):264-270. PubMed ID: 33086362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.